Personalized Medicine in Severe Asthma: From Biomarkers to Biologics

Chun Yu Chen, Kang Hsi Wu, Bei Cyuan Guo, Wen Ya Lin, Yu Jun Chang, Chih Wei Wei, Mao Jen Lin*, Han Ping Wu*

*此作品的通信作者

研究成果: 期刊稿件文獻綜述同行評審

4 引文 斯高帕斯(Scopus)

摘要

Severe asthma is a complex and heterogeneous clinical condition presented as chronic inflammation of the airways. Conventional treatments are mainly focused on symptom control; however, there has been a shift towards personalized medicine. Identification of different phenotypes driven by complex pathobiological mechanisms (endotypes), especially those driven by type-2 (T2) inflammation, has led to improved treatment outcomes. Combining biomarkers with T2-targeting monoclonal antibodies is crucial for developing personalized treatment strategies. Several biological agents, including anti-immunoglobulin E, anti-interleukin-5, and anti-thymic stromal lymphopoietin/interleukin-4, have been approved for the treatment of severe asthma. These biological therapies have demonstrated efficacy in reducing asthma exacerbations, lowering eosinophil count, improving lung function, diminishing oral corticosteroid use, and improving the quality of life in selected patients. Severe asthma management is undergoing a profound transformation with the introduction of ongoing and future biological therapies. The availability of novel treatment options has facilitated the adoption of phenotype/endotype-specific approaches and disappearance of generic interventions. The transition towards precision medicine plays a crucial role in meticulously addressing the individual traits of asthma pathobiology. An era of tailored strategies has emerged, allowing for the successful targeting of immune-inflammatory responses that underlie uncontrolled T2-high asthma. These personalized approaches hold great promise for improving the overall efficacy and outcomes in the management of severe asthma. This article comprehensively reviews currently available biological agents and biomarkers for treating severe asthma. With the expanding repertoire of therapeutic options, it is becoming increasingly crucial to comprehend the influencing factors, understand the pathogenesis, and track treatment progress in severe asthma.

原文英語
文章編號182
期刊International Journal of Molecular Sciences
25
發行號1
DOIs
出版狀態已出版 - 22 12 2023

文獻附註

Publisher Copyright:
© 2023 by the authors.

指紋

深入研究「Personalized Medicine in Severe Asthma: From Biomarkers to Biologics」主題。共同形成了獨特的指紋。

引用此